Can I Take Vitamin B12 with Metformin?

The direct answer

Vitamin B12 and metformin are safe to take together, and doing so does not create a drug interaction in the pharmacological sense. Metformin is a biguanide used to lower blood glucose in type 2 diabetes; vitamin B12 (cobalamin) is a water-soluble vitamin required for red blood cell formation and nerve myelin maintenance. The concern clinicians raise is not toxicity from combining them but the opposite: metformin appears to reduce the body's ability to absorb dietary B12 over months to years of use, so supplementation is often a corrective measure rather than an optional add-on.

That combination of facts, no pharmacokinetic interaction plus a real absorption effect running in one direction, is the reason B12 supplementation alongside metformin is common clinical practice rather than something to avoid.

What is established, what is plausible, and what is not settled

Established: Metformin does not alter the pharmacokinetics of vitamin B12 (absorption pathway aside), and B12 does not affect metformin's renal clearance or glucose-lowering effect. Observational and trial literature going back over two decades has repeatedly found lower serum B12 in metformin users compared with non-users or with placebo, particularly with longer duration and higher cumulative dose. This association is well documented enough that it appears in general clinical teaching about metformin's side-effect profile.

Plausible but not fully proven: The commonly cited mechanism is that metformin interferes with a calcium-dependent step in B12-intrinsic factor uptake at the terminal ileum. This mechanism is widely referenced in the literature and is a reasonable explanation for the observed association, but it has not been established with the same certainty as, say, an FDA label warning would imply. Whether one form of supplemental B12 (methylcobalamin versus cyanocobalamin) more effectively reverses metformin-associated deficiency, or whether it matters at all for nerve-related symptoms specifically, remains unresolved.

Not established from the material reviewed here: A single, universally agreed prevalence figure for metformin-associated B12 deficiency. Published estimates vary by population, dose, duration, and the lab threshold used to define deficiency, and pinning any single percentage to "metformin users" as a general statement overstates the precision of the evidence. Any specific number a reader encounters online, including in earlier versions of pages like this one, should be treated as needing verification against the primary study before being repeated as fact.

Why this happens: the proposed mechanism

Dietary B12 normally binds intrinsic factor, a protein made by the stomach, and the resulting complex attaches to receptors in the terminal ileum in a process that appears to depend on calcium availability at the cell membrane. The leading explanation in the literature is that metformin interferes with that calcium-dependent step, reducing how efficiently the B12-intrinsic factor complex is taken up. This is described as a pharmacodynamic effect on absorption rather than a pharmacokinetic drug-drug interaction, because metformin is not shown to change what happens to B12 once it is inside the body, and B12 does not change how metformin is handled by the kidneys.

The practical implication of that distinction is that supplementing B12 does not need to work around metformin's mechanism of action. It simply needs to supply more B12 than the impaired absorption pathway is losing, which oral supplementation at typical over-the-counter doses is generally able to do because higher intakes are absorbed partly through passive diffusion elsewhere in the gut, independent of the ileal receptor.

Who tends to be watched more closely

Not everyone on metformin develops low B12, and the risk is not evenly distributed. Clinicians generally pay closer attention to:

• People on higher metformin doses and those who have taken it for several years rather than months
• Older adults, who may already have reduced gastric acid output and lower baseline B12 absorption independent of any medication. A 2024 review of B12 deficiency in older adults describes multiple overlapping causes of impaired absorption in this age group and its association with several geriatric syndromes, which is relevant background even though it is not specific to metformin use (Vitamin B12 deficiency in the elderly and its associations with geriatric syndromes, 2024)
• Vegetarians and vegans, who take in little or no dietary B12 to begin with
• People also taking proton pump inhibitors or other acid-suppressing medications, since gastric acid supports part of the natural B12 absorption pathway

None of this amounts to a precise risk score for an individual patient. It is a reasonable basis for a clinician to decide whether to check B12 sooner rather than waiting for a routine annual panel.

Why low B12 matters if you are on metformin

The most clinically important overlap is with peripheral neuropathy. B12 is needed for normal nerve myelin, and low B12 can cause numbness, tingling, or burning sensations in the hands and feet. Diabetic peripheral neuropathy from chronic high blood sugar can produce the exact same symptoms through an entirely different mechanism. Without a blood test, a clinician cannot reliably tell the two apart, which means new or worsening neuropathic symptoms in someone on metformin should prompt a B12 check rather than an automatic assumption that the diabetes itself is the cause.

Longer-standing, more severe B12 deficiency can also cause macrocytic anemia (large, poorly functioning red blood cells, detected via a routine complete blood count showing elevated mean corpuscular volume) and, less commonly, cognitive or mood changes. These are downstream consequences of deficiency generally, not specific to metformin, but metformin's association with reduced absorption is one plausible route to reaching a deficient state in the first place.

Supplementing B12 while on metformin

Cyanocobalamin and methylcobalamin are the two forms most often used. Cyanocobalamin is the more studied, less expensive, and more stable of the two, and it converts to active cobalamin forms in the body. Methylcobalamin is already in an active form and is sometimes preferred by clinicians treating neuropathy, though robust head-to-head trial data comparing the two specifically in metformin users are limited, so any claim that one is clearly superior for this purpose should be treated as clinical preference rather than settled evidence.

Doses commonly used in practice range from around 1,000 mcg of oral B12 daily for general prevention and mild depletion, up to higher oral doses or a structured intramuscular repletion schedule for confirmed, more significant deficiency. These are general patterns seen in clinical practice and published protocols, not a personalized dosing recommendation; the right dose, form, and duration for any individual depends on their lab values, symptoms, and other health conditions, and should be set by the prescriber who ordered the B12 level, not chosen independently based on an online article.

No dose separation between metformin and B12 is required. They can be taken at the same time, with or without food. The oral high-dose route works in part because a fraction of B12 is absorbed passively throughout the gut at higher intakes, which does not depend on the calcium-related ileal step that metformin is thought to affect.

According to the National Institutes of Health Office of Dietary Supplements, no tolerable upper intake level has been set for vitamin B12 because excess amounts are excreted in urine without established evidence of toxicity at typical supplemental doses (NIH ODS Vitamin B12 Fact Sheet for Health Professionals). People with significant chronic kidney disease should still confirm supplementation with their treating clinician, since kidney disease can alter B12 metabolism and how lab values should be interpreted, independent of any toxicity concern.

When monitoring is reasonable

The ADA Standards of Care addresses periodic vitamin B12 monitoring for people on long-term metformin, particularly those with peripheral neuropathy or anemia, as part of its broader diabetes management guidance (ADA Standards of Care, current supplement issue). Readers should verify the exact current wording against the live guideline rather than relying on a paraphrase, since guideline language is updated periodically. In practice, monitoring intervals vary by clinic and are not rigidly standardized, which is part of why some patients report never having had a B12 level checked despite years on metformin.

Evidence-status interaction assessment: metformin and vitamin B12

What to verify with a prescriber or pharmacist before assuming anything above applies to you: your current serum B12 level and how long it has been since it was last checked, whether you take an acid-suppressing medication, your metformin dose and duration, and whether any neuropathic symptoms you have could be from low B12 rather than diabetes itself.

When to seek care rather than self-manage

New or worsening numbness, tingling, burning, or weakness in the hands or feet while on metformin is worth a prompt visit rather than waiting for a routine annual check, since the cause could be B12 deficiency, diabetic neuropathy, or both, and the two are treated differently. Symptoms of significant anemia, such as marked fatigue, pallor, or shortness of breath, also warrant timely evaluation rather than starting supplementation on your own and waiting to see if it helps.